-
公开(公告)号：US11779606B2
公开(公告)日：2023-10-10
申请号：US17155960
申请日：2021-01-22
发明人： Heiko Schuster , Franziska Hoffgaard , Jens Fritsche , Oliver Schoor , Toni Weinschenk , Daniel Johannes Kowalewski , Chih-Chiang Tsou
IPC分类号： A61K39/00 , A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47 , A61K45/00
CPC分类号： A61K35/17 , A61K38/08 , A61K39/001102 , A61K39/001114 , A61K39/001118 , A61K39/12 , A61K39/39 , A61K39/39558 , A61K45/06 , A61P35/00 , A61P35/02 , C07K7/06 , C07K14/4748 , C07K14/5434 , C07K16/244 , C07K16/2818 , C07K16/2821 , C12N5/0636 , A61K45/05 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55516 , A61K2039/55533 , A61K2039/55538 , A61K2039/55561 , A61K2039/572 , A61K2039/585
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
82.发明公开公开(公告)号：US20230241115A1
公开(公告)日：2023-08-03
申请号：US18173177
申请日：2023-02-23
发明人： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
83.发明公开公开(公告)号：US20230241113A1
公开(公告)日：2023-08-03
申请号：US18170698
申请日：2023-02-17
发明人： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
84.发明公开公开(公告)号：US20230241108A1
公开(公告)日：2023-08-03
申请号：US18164407
申请日：2023-02-03
发明人： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC分类号： A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
85.发明申请公开(公告)号：US20190231829A1
公开(公告)日：2019-08-01
申请号：US16192172
申请日：2018-11-15
发明人： Brian Goodman , Holly Ponichtera , Andrea Itano , Mark Bodmer , Taylor A. Cormack , Maria Sizova , Carolina Baez-Giangreco , Duncan McHale
IPC分类号： A61K35/744 , A61P37/06
CPC分类号： A61K35/744 , A61K45/05 , A61K2035/115 , A61P17/06 , A61P29/00 , A61P37/06 , C12N1/20 , C12R1/225
摘要： Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents.
-
公开(公告)号：US20180250375A1
公开(公告)日：2018-09-06
申请号：US15747671
申请日：2016-07-25
CPC分类号： A61K39/04 , A61K9/0019 , A61K35/761 , A61K39/12 , A61K39/39 , A61K45/05 , A61K2039/5256 , A61K2039/545 , A61P31/06 , C07K14/005 , C07K14/35 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2710/10321 , C12N2710/10341 , C12N2710/10343 , C12N2740/16234 , C12N2760/18534
摘要： The present invention relates to methods for inducing an immune response, in particular methods for inducing an immune response against mycobacterial infections or disease comprising (i) at least one administration of a polypeptide Rv1196 related antigen and at least one administration of an adenovirus encoding a Rv1196 related antigen or (ii) at least one administration of a polypeptide Rv0125 related antigen and at least one administration of an adenovirus encoding a Rv0125 related antigen. Associated compositions, adenoviral constructs and polynucleotide sequences are also provided.
-
公开(公告)号：US20180162943A1
公开(公告)日：2018-06-14
申请号：US15579311
申请日：2016-06-03
发明人： Scott ANTONIA
CPC分类号： C07K16/2818 , A61K39/0011 , A61K39/39541 , A61K39/39558 , A61K45/05 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/545 , A61K2039/572 , A61K2300/00 , A61P11/00 , A61P31/00 , A61P35/00 , C07K2317/76
摘要： A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and cluster of differentiation 40 (CD40) ligand. In some embodiments, the checkpoint inhibitor comprises an anti-programmed death-1 (anti-PD-1) antibody (e.g., BMS 936558), anti-programmed death ligand-1 (anti-PD-L1) antibody (e.g., cloneMIHI), anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) antibody (e.g., Ipilimumab, BMS), or any combination thereof.
-
88.发明申请公开(公告)号：US20180161433A1
公开(公告)日：2018-06-14
申请号：US15631843
申请日：2017-06-23
IPC分类号： A61K45/00 , A61P35/00 , A61K31/711 , A61K39/39 , A61K38/03 , A61K39/02 , A61K39/12 , A61K9/00
CPC分类号： A61K39/0011 , A61K9/0024 , A61K31/711 , A61K38/03 , A61K39/02 , A61K39/12 , A61K39/385 , A61K39/39 , A61K45/05 , A61K2039/5152 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/585 , A61K2039/627 , A61P35/00
摘要： This invention describes novel immunogenic complexes, which are designed to trigger a robust host immune response against cancer cells by co-opting the immune system's natural ability to eliminate pathogen-infected host cells. The immunogenic complexes, referred to as microbial mimetics (MM) have unique physical and biochemical properties, which are designed to simulate a pathogenic infection of similar sized bacteria and viruses, permitting tumor-associated and tumor-specific peptide antigens to be presented to immune cells as microbial constituents. The MM are well-suited to mimic a systemic infection with microbe sized particles comprised largely of tumor antigens. Under this framework, tumor cells may be eliminated in the ensuing immune response.The microbial mimetics exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The MM constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo.
-
公开(公告)号：US09867871B2
公开(公告)日：2018-01-16
申请号：US14362589
申请日：2012-08-20
申请人： Sandeep Jain
发明人： Sandeep Jain
CPC分类号： A61K38/465 , A61K9/0048 , A61K31/465 , A61K45/05 , A61K45/06 , C12Q1/6816 , C12Y301/21001 , A61K2300/00
摘要： Provided herein is a composition and a method for treating nucleic acid-related eye disease.
-
公开(公告)号：US20170360760A1
公开(公告)日：2017-12-21
申请号：US15534166
申请日：2015-12-16
发明人： Olesya KHARENKO , Peter Ronald YOUNG , Samuel David BROWN , Bryan Cordell DUFFY , Shuang LIU , Peter GUZZO
IPC分类号： A61K31/422 , C07D413/04 , A61K31/435 , A61K31/4184 , A61K45/00 , C07D413/14 , C07D261/06
CPC分类号： A61K31/422 , A61K31/4184 , A61K31/435 , A61K31/437 , A61K31/4439 , A61K45/05 , A61K45/06 , A61K2300/00 , A61P3/00 , A61P9/00 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , C07D261/06 , C07D413/04 , C07D413/14 , C07D471/04 , Y02A50/467
摘要： The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
105 条记录 (耗时 0.03 秒)
